Sort

Search

Search Bar
09/02/2022 Cortical microstructure in primary progressive aphasia: a multicenter study
Illan-Gala, I, Montal, V, Borrego-Ecija, S, Mandelli, ML, Falgas, N, Welch, AE, Pegueroles, J, Santos-Santos, M, Bejanin, A, Alcolea, D, Dols-Icardo, O, Belbin, O, Sanchez-Saudinos, MB, Bargallo, N, Gonzalez-Ortiz, S, Llado, A, Blesa, R, Dickerson, BC, Rosen, HJ, Miller, BL, Lleo, A, Gorno-Tempini, ML, Sanchez-Valle, R, Fortea, J. Cortical microstructure in primary progressive aphasia: a multicenter study. Alzheimers Research & Therapy. 2022; 14(1)DOI:10.1186/s13195-022-00974-0. PMID:35139897. IF:9.000(Q1/1D).
09/02/2022 Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population
Cebrian-Cuenca, AM, Mata-Cases, M, Franch-Nadal, J, Mauricio, D, Orozco-Beltran, D, Consuegra-Sanchez, L. Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population. European Journal of Preventive Cardiology. 2022; 28(18)DOI:10.1093/eurjpc/zwaa073. PMID:33733654. IF:8.300(Q1/2D).
09/02/2022 Interaction between rs10830962 polymorphism in MTNR1B and lifestyle intervention on maternal and neonatal outcomes: secondary analyses of the DALI lifestyle randomized controlled trial
van Poppel, MNM, Corcoy, R, Hill, D, Simmons, D, Mendizabal, L, Zulueta, M, Simon, L, Desoye, G, Perez, JMA, Kautzky-Willer, A, Harreiter, J, Damm, P, Mathiesen, E, Jensen, DM, Andersen, LLT, Dunne, F, Lapolla, A, Dalfra, MG, Bertolotto, A, van Poppel, M, Jelsma, JGM, Snoek, FJ, Galjaard, S, Wender-Ozegowska, E, Zawiejska, A, Devlieger, R, DALI Core Investigator Grp. Interaction between rs10830962 polymorphism in MTNR1B and lifestyle intervention on maternal and neonatal outcomes: secondary analyses of the DALI lifestyle randomized controlled trial. AMERICAN JOURNAL OF CLINICAL NUTRITION. 2022; 115(2)DOI:10.1093/ajcn/nqab347. PMID:34669935. IF:7.100(Q1/2D).
08/02/2022 Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
Hughes, DA, Aguiar, P, Lidove, O, Nicholls, K, Nowak, A, Thomas, M, Torra, R, Vujkovac, B, West, ML, Feriozzi, S. Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?. Orphanet Journal of Rare Diseases. 2022; 17(1)DOI:10.1186/s13023-022-02181-4. PMID:35135579. IF:3.700(Q2/4D).
08/02/2022 Non-invasive oxygenation support in acutely hypoxemic COVID-19 patients admitted to the ICU: a multicenter observational retrospective study
Wendel-Garcia, PD, Mas, A, Gonzalez-Isern, C, Ferrer, R, Manez, R, Masclans, JR, Sandoval, E, Vera, P, Trenado, J, Fernandez, R, Sirvent, JM, Martinez, M, Ibarz, M, Garro, P, Lopera, JL, Bodi, M, Yebenes-Reyes, JC, Triginer, C, Vallverdu, I, Baro, A, Bodi, F, Saludes, P, Valencia, M, Roche-Campo, F, Huerta, A, Cambra, FJ, Barbera, C, Echevarria, J, Penuelas, O, Mancebo, J, UCIsCAT Study Grp. Non-invasive oxygenation support in acutely hypoxemic COVID-19 patients admitted to the ICU: a multicenter observational retrospective study. CRITICAL CARE. 2022; 26(1)DOI:10.1186/s13054-022-03905-5. PMID:35135588. IF:15.100(Q1/2D).
08/02/2022 Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19
Pinana, JL, Garcia-Sanz, R, Martino, R, Garcia-Rao, M, Martin-Martin, GA, Risco-Galvez, I, Tormo, M, Martinez-Barranco, P, Marcos-Corrales, S, Calabuig, M, Conesa, V, Teruel, A, Ruiz-Perez, S, Solano, C, Navarro, D, Cedillo, A, Sureda, A. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021006326. PMID:34905620. IF:7.500(Q1/2D).
08/02/2022 Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
Onate, G, Bataller, A, Garrido, A, Hoyos, M, Arnan, M, Vives, S, Coll, R, Tormo, M, Sampol, A, Escoda, L, Salamero, O, Garcia, A, Bargay, J, Aljarilla, A, Nomdedeu, JF, Esteve, J, Sierra, J, Pratcorona, M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2020004136. PMID:34516636. IF:7.500(Q1/2D).
08/02/2022 Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
Menghrajani, K, Gomez-Arteaga, A, Madero-Marroquin, R, Zhang, MJ, Bo-Subait, K, Sanchez, J, Wang, HL, Aljurf, M, Assal, A, Bacher, VU, Badawy, SM, Bejanyan, N, Bhatt, VR, Bredeson, C, Byrne, M, Castillo, P, Cerny, J, Chhabra, S, Ciurea, SO, DeFilipp, Z, Farhadfar, N, Gadalla, S, Gale, RP, Ganguly, S, Gowda, L, Grunwald, MR, Hashmi, S, Hildebrandt, G, Kanakry, CG, Kansagra, A, Khimani, F, Krem, M, Lazarus, H, Liu, HT, Martino, R, Michelis, FV, Nathan, S, Nishihori, T, Olsson, R, Reshef, R, Rizzieri, D, Rowe, JM, Savani, BN, Seo, S, Sharma, A, Solh, M, Ustun, C, Verdonck, LF, Hourigan, C, Sandmaier, B, Litzow, M, Kebriaei, P, Weisdorf, D, Zhang, YM, Tallman, MS, Saber, W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021004881. PMID:34551064. IF:7.500(Q1/2D).